ErVaccine Technologies

ErVaccine Technologies, spin off from Centre Léon Bérard (CLB) / Cancer Research Center of Lyon (CRCL), was founded in October 2019 by Prof. Stéphane Depil, MD, PhD, onco-hematologist at CLB, based on the research work from his academic lab. Currently at a preclinical stage of development, the company specializes in the development of next generation cancer vaccines, and cell therapies based on modified T lymphocytes, targeting new families of non-conventional tumor antigens such as those derived from endogenous retroviruses (identified and patented therapeutic targets).

A first financing round with Seventure Partners was carried out end of 2020, after a seed phase allowed by a French Tech BPI grant, and “Proof of Concept” funding from the Cancéropôle Lyon Auvergne-Rhône-Alpes. This funding will allow to lead a vaccine candidate to a first phase I trial (clinical proof of concept) in advanced or metastatic “triple negative” breast cancer, while other indications will then be targeted (proprietary know-how to adapt therapeutic products to the disease).